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Cancer and diabetes are among the most common diseases in western societies. Epidemiological studies have shown that diabetic
patients have a significantly higher risk of developing a number of different types of cancers and that individuals with comorbidity
(cancer and diabetes/prediabetes) have a poorer prognosis relative to nondiabetic cancer patients. The increasing frequency of
comorbidity of cancer and diabetes mellitus, mainly type 2 diabetes, has driven the development of therapeutic interventions that
target both disease states. There is strong evidence to suggest that balancing the sphingolipid rheostat, ceramide—sphingosine—
sphingosine-1-phosphate (S1P) is crucial in the prevention of diabetes and cancer and sphingosine kinase/S1P modulators are
currently under development for the treatment of cancer and diabetes. This paper will highlight some of the complexities inherent
in the use of the emerging sphingosine kinase/S1P modulators in the treatment of comorbidity of diabetes and cancer.
1. Introduction
Cancer and diabetes mellitus are two of the most prevalent
diseases worldwide. An estimated 347 million people world-
wide suffer from diabetes [1].TheWorldHealth Organization
(WHO) projects this disease to become the 7th leading cause
of death by 2030 [2]. Cancer is the 2ndmost prevalent disease
worldwide [3, 4]. Whilst there is an increasing awareness
of a strong association between the two diseases, both for
cancer incidence and prognosis, the biologic links between
diabetes and cancer risk are not well defined [5–7]. Type 2
diabetic patients have a greater propensity to develop cancer,
and cancer and diabetes share many risk factors [8]. Some
epidemiological studies suggest increasedmortality in cancer
patients with preexisting diabetes [9]. With the increasing
likelihood of comorbidity of cancer and diabetes and the
potential of increased mortality in these patients [9–11],
understanding the aetiology underlying both diseases will aid
in the development of more efficacious treatments.
Sphingosine kinase (SphK) is an important signalling
enzyme that catalyses the phosphorylation of the lipid sphin-
gosine to form sphingosine-1-phosphate (S1P) and has been
implicated in the pathology of both diabetes and cancer
[7, 12–17]. SphK plays a critical role in balancing the relative
levels of the two signalling molecules controlling cellular
metabolic processes such as cell proliferation, survival, apop-
tosis, adhesion, and migration [18–20]. Hence there is a
strong motivation for the development of SphK/S1P mod-
ulators for therapeutic interventions to target patients with
comorbidity of diabetes and cancer. This paper, as part of the
special issue on “Hijacking themetabolic regulation in cancer
and diabetes,” aims to highlight the complications arising
from targeting the SphK1/S1P rheostat, by the S1P modula-
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2. Type 1 and Type 2 Diabetes
Type 1 and type 2 diabetes are complex diseases characterised
by progressive failure of the insulin producing pancreatic
𝛽-cells [21]. The mechanisms of pancreatic 𝛽-cell death in
type 1 and type 2 diabetes have very few similarities [22].
Type 1 diabetes is caused by an autoimmune attack resulting
in the loss of the insulin producing 𝛽-cells and loss of
insulin secretion whereas type 2 diabetes is characterised
by insulin resistance, which can lead to a relative state of
hyperinsulinaemia (overproduction of insulin) to maintain
normal glycaemia and eventually results in 𝛽-cell failure.
Approximately 10% of diabetic patients have type 1 diabetes
(usually starting in childhood or younger age), and these
patients have an absolute requirement for insulin therapy
requiring daily dosage of insulin. Type 2 diabetes is the most
common, making up approximately 90% of all cases. In most
instances these patients are noninsulin dependent; however,
over time, they may require insulin to maintain glycaemic
control.The onset of type 2 diabetes is usually later in life and
is associated with obesity and a sedentary lifestyle. Saturated
fatty acids associated with obesity, such as palmitate, are
lipotoxic towards the pancreatic𝛽-cells, exerting a double hit:
insulin resistance and reduced pancreatic 𝛽-cell survival [23,
24]. Skeletal muscle also plays a major role in the pathology
of insulin resistance as this tissue is important for whole body
insulin-stimulated glucose removal [25]. Thus perturbation
of insulin signalling in skeletal muscle is a key factor in type
2 diabetes development. Complications of both type 1 and
type 2 diabetes include cardiovascular disease, neuropathy,
retinopathy, and kidney failure [21].
3. Obesity, Diabetes, and Cancer
Obesity is a common risk factor linking type 2 diabetes and
cancer and is covered extensively in a recent review [6]. Type
2 diabetes and obesity have been associated independently,
and in common, with increased cancer risk [8]. This risk
may be attributed to underlying metabolic conditions such
as insulin resistance, hyperinsulinaemia, hyperglycaemia,
and inflammation, which all influence the development
and progression of neoplasia [26]. Treatment of diabetes
with glucose-lowering therapies, such as metformin, has
been reviewed extensively and, in general, the treatment of
diabetic patients with metformin has been shown to lead to
a reduced cancer risk and results in a better overall survival
[5, 10, 11, 27]. The effects of cancer drugs on coexisting
diabetes have been less well studied and in some cases cancer
therapies may cause increased risk of diabetes development
[27, 28]. A signalling pathway crucial to the onset/progression
of cancer and diabetes is the phosphatidylinositol-3-kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR) path-
way [29]. Hyperactivation of this pathway is known to
result in increased cell proliferation, decreased apoptosis,
and cancer [28]. Inhibitors of this pathway are used for
cancer therapy but such drugs may result in impaired insulin
responses and insulin resistance leading to the development
of type 2 diabetes [28]. Cancer chemotherapy with drugs
such as 5-fluorouracil, androgen-deprivation therapy, and
carboplatin has been reported to be associated with drug-
induced diabetes or the worsening of preexisting diabetes
and is reviewed in [6]. More recently, manipulation of
the sphingosine kinase/sphingosine-1-phosphate (SphK/S1P)
signalling pathway using generic and specific inhibitors has
been investigated as a potential cancer therapy [13–15, 30–
34]. However, there is a fine balance between swinging the
ceramide-SphK/S1P pendulum in favour of cancer preven-
tion/treatment and the onset of diabetes (Figure 1). This
conundrum is discussed in more detail below.
4. Sphingosine Kinase
There are two major isoforms of SphK (SphK1 and SphK2)
with diverse and compensatory actions [35]. SphK mediates
the balance between the proapoptotic effects of ceramide
and sphingosine substrates and the antiapoptotic effects
of sphingosine-1-phosphate (S1P), a phosphorylation bal-
ance system more aptly named “the sphingolipid rheo-
stat” [18, 36, 37]. SphK phosphorylates sphingosine to pro-
duce sphingosine-1-phosphate (S1P) andmodulates autocrine
(intracellular) and paracrine (extracellular) functions. S1P
binds mainly to five specific G-protein-coupled receptors
(GPCRs), S1P
1−5
[38]. One or more of the five S1P receptor
subtypes are found on the surface of most cells [38]. S1P
activation and function is cell type and S1P receptor type
specific. In skeletal muscle cells, S1P has been shown to
increase glucose uptake through the transactivation of the
insulin receptor [39] whereas in epithelial cells S1P inhibits
AKT activity and interrupts insulin signalling and cell prolif-
eration through the S1P
2
receptor subtype [40]. The SphK1
isoform has two major subtypes, SphK1a and SphK1b, and
emerging evidence indicates that SphK1a and SphK1b have
common and differing interacting partners [41] and, through
such interactions, each subtype is able to influence diverse
downstream signalling pathways [42]. Tipping the balance in
favour of ceramide accumulation has been shown to cause
insulin resistance whereas SphK1 prevents ceramide accumu-
lation by promoting its metabolism to S1P and augmenting
insulin action [16, 43, 44]. In contrast, overexpression of
SphK1 is associated with increased cancer risk [7, 12]. As
mentioned previously, inhibitors of SphK1 are currently
being explored for cancer treatment; however, with the high
probability of comorbidity of cancer and diabetes [5, 6], the
possibility of cancer treatments such as SphK1 inhibitors
promoting insulin resistance may have dire consequences for
cancer survivors.
5. SphK and S1P Inhibitors and
Diabetes/Obesity Complications
The drive towards the use of SphK/S1P pharmaceutical
inhibitors for cancer treatment has key significance for
diabetic patients. The “sphingolipid rheostat” is implicated
in controlling the balance between cell proliferation and
apoptosis. As such, activation of S1P has been shown to be
critical in protecting pancreatic𝛽-cells (the cells that produce,
store, and release insulin) from apoptosis and preventing



















Figure 1: The swinging pendulum. Overexpression of SphK1 activates S1P and favours cell proliferation and survival. S1P overexpression is
associated with cancer progression, type 2 diabetes complications such as inflammation, metabolic dysfunction, cardiovascular problems,
nephropathy, retinopathy, and neuropathy. Loss of S1P can affect pancreatic 𝛽-cell proliferation and is associated with the progression of both
type 1 and type 2 diabetes. Therapeutic intervention involving binding to specific S1P receptors may swing the pendulum in favour of more
promising comorbidity treatments. Cer: ceramide, Sph: sphingosine, SphK1: sphingosine kinase 1, S1P: sphingosine-1-phosphate.
the development of diabetes in obese mice [43]. Abnormal
islet function is central to the development of type 1 and type 2
diabetes [45]; therefore the danger of SphK/S1P inhibitors for
cancer therapy is that they may increase the risk of diabetes
development. In support of S1P activation in diabetic control,
S1P has been shown to be important for insulin synthesis and
secretion in a rat insulinoma cell line [46], muscle insulin
resistance [16], and adiponectin action (increased sensitivity,
decreased inflammation, and prosurvival) [47, 48]. The dia-
betic mouse model, KK/Ay, demonstrates a morbidly obese
phenotype with metabolic abnormalities that are common
in diabetic patients [49]. Overexpression of SphK1 in KK/Ay
diabetic mice has been shown to significantly reduce blood
glucose levels and improve the overall health of the animals
whilst having no effect on normal animals [17].
There is a strong risk of cardiovascular diseases and
heart failure in diabetic patients [50–55]. Several studies and
reviews have emphasised the importance of SphK1/S1P in car-
dioprotection [17, 56–58]. A typical feature of the phenotype
of animal models of diabetes is an increased accumulation of
glycogen in the myocardium which leads to cardiomyopathy
[59]. Such glycogen accumulation, which is typical of KK/Ay
diabetic mice, was absent after adenoviral mediated (Ad-
SphK1) overexpression of SphK1, potentially improving the
function of the heart [17]. Moreover, impairment of liver and
kidney function associated with the diabetic phenotype was
also reversed in the Ad-SphK1 diabetic mice [17].
Atherosclerosis, the hardening of the arteries eventually
leading to heart attacks and peripheral vascular disease, is
accelerated in type 1 and type 2 diabetic patients [60–62].
Interactions between monocytes and endothelial cells are
critical early events in the development of atherosclerosis
[63]. In the nonobese diabetic mouse model (NOD/LtJ), a
mouse model of spontaneous type 1 diabetes development
(autoimmune destruction of the pancreatic islet cells), S1P
minimises the monocyte/endothelial interaction that occurs
in elevated glucose environments [64, 65].
Silent myocardial ischaemia is frequently presented in
diabetic patients and this is reviewed in [66]. Activation
of SphK1 has been shown to protect isolated mouse hearts
against ischaemia/reperfusion injury [67], to have a cardio-
protective effect of ischaemic preconditioning in mice and
ischaemia/reperfusion injury [67–69] and to play a role in
recovery of haemodynamic function after ischaemic injury
[69]. In addition, SphK1 is important in the maintenance
of blood vessel integrity and mice depleted of SphK1 have
increased vascular leakiness [70]. Wound healing is also
problematic in diabetic patients; however, SphK1/S1P activa-
tion has recently shown promise in the improvement of the
wound healing process in diabetic rats [71].
Prevention of diabetes and improved pancreatic islet
transplantation outcomes through pharmacological manip-
ulation of the sphingolipid rheostat in favour of SphK1 has
been shown to (i) promote insulin release, (ii) promote
establishment and maintenance of intraislet vasculature,
(iii) improve glucose sensing, and (iv) play a role in the
prevention/treatment of the immune-mediated attack [45].
SphK1/S1P also plays a prosurvival role in primary hepato-
cytes and protects against liver injury [72].
On the other hand, S1P activation is not all positive for
diabetic patients. S1P has been shown to be significantly
increased in the blood of obese humans and mice and
elevated S1P levels in humans have been correlated with
metabolic dysfunction, cardiovascular problems, high body
mass index (BMI), and large waist circumference, all fac-
tors associated with obesity [73]. Complications associated
with obesity are also linked to cancer risk [10]. Wang
and colleagues demonstrated that SphK1 overexpression
was associated with adipose proinflammatory responses and
insulin resistance in diet-induced obese mice and obese
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diabetic humans [74]. In agreement with these findings
Tous and colleagues demonstrated that activation of SphK1
in adipocytes (fat cells) triggered a cytokine inflammatory
response whereas suppression of SphK1 activation lowered
the expression of proinflammatory cytokines in adipose
tissue of Zucker diabetic fatty rats [75]. In these experimental
scenarios, inhibition of SphK1 was suggested as a therapeutic
tool for the prevention and treatment of inflammation asso-
ciated with obesity and type 2 diabetes [75]. Although there
are several studies and reviews emphasising the importance
of SphK1/S1P in cardioprotection (as mentioned above),
elevated SphK1/S1P levels have also been associated with
the negative effects of cardiovascular diseases linked to
diabetes. For example, in one study SphK1 inhibition ame-
liorated angiotensin II-induced acute hypertension [76] and
in another study deregulation of specific S1Ps played a role
in cardiac microvascular dysfunction [77]. A growing list of
adverse diabetic complications is believed to be involved with
high levels of SphK1/S1P expression including neuropathy
[36, 78, 79], retinopathy [80–84], nephropathy [85], and
cancer [5, 6, 8]. The complexities of insulin resistance, with
reference to the onset of diabetes and the modulation of S1P
signalling, are discussed comprehensively in recent articles
by Fayyaz and colleagues [86, 87]. In summary, the major
apparent hurdle is that therapies targeting the SphK/S1P
rheostat in cancer patients (for cancer therapy) may prove
to be a double-edged sword where predisposing conditions
such as obesity and diabetes are also presented. In addition,
complications associatedwith the use of SphK1/S1P inhibitors
may be that cancer patients are more susceptible to diabetes
development. The multifaceted nature of SphK complicates
the generation of SphK/S1P inhibitors as therapies for cancer.
6. SphK and S1P Inhibitors:
Obesity/Diabetes/Cancer Conundrum
The development of treatment regimes to avoid complica-
tions arising from the presence of combined disease states,
such as cancer and diabetes, is a major challenge: in this
case, to balance cancer cell apoptosis and reduce disease
complications whilst protecting pancreatic 𝛽-cell prolifera-
tion, it is becoming increasingly apparent that balancing the
sphingosine rheostat is crucial in the development of many
types of cancer and also diabetes; however, the opposing
effects of SphK/S1P inhibitors on diabetes and cancer are a
conundrum. It is unknown whether S1P activation influences
both type 1 and type 2 diabetes outcomes such as mechanism
of 𝛽-cell death or insulin resistance in skeletal muscle. Fur-
thermore, obese cancer patients could be at heightened risk of
diabetes if treated with SphK/S1P inhibitors and this concept
needs to be considered in future research in SphK/S1P
inhibitor design and treatment. S1P agonists and functional
antagonists (S1P receptor modulators) are in development to
target specific S1P receptor subtypes to maximise therapeutic
efficacy [88, 89]. FTY720 (fingolimod) is a first generation
S1P modulator under consideration for the treatment of
cancer and diabetes, however not necessarily for comorbidity
therapy. FTY720 is a S1P analogue that mimics S1P as
an agonist of all the S1P receptors except S1P
2
[90–92].
Despite this, it also acts as a functional S1P
1
receptor antag-
onist, reviewed in [93]. The fact that FTY720 does not bind
to S1P
2
has created much interest for diabetes/cancer therapy
advocates. There are mixed results reported to date with the
use of FTY720 for cancer treatment. Recent advances have
shown the use of FTY720 and its derivatives to be promising
potential therapies for cancers such as intestinal and colorec-
tal cancer [94–97], leukaemia [95, 98, 99], ovarian cancer
[100], triple-negative breast cancers [101], and increased
sensitivity to radiation of breast cancer cells [102]. Moreover,
FTY720 inhibits melanoma growth and invasion in 3D
culture in vitro (NKH, unpublished results). On the other
hand, FTY720 decreased sensitivity of breast cancer cells
overexpressing the oncogene pp32r1 [103] andHER2 targeted
therapy with lapatinib [104] potentially compromising the
efficacy of FTY720 in some breast cancer clinical cotreatment
regimes.
SphK1/S1P inhibitors as therapies for diabetes are also
problematic. The effect of FTY720 in various animal models
of type 1 diabetes is summarised by Jessup and colleagues
[45]. The efficacy of FTY720 ranges from complete preven-
tion of diabetes, short-term prevention, and—depending on
the disease stage and time point of drug administration—
diminished efficacy from 20–100% [45]. In recent studies,
FTY720 has been shown to inhibit the development of obesity
in high fat fed mice, by modulation of adipogenesis and
lipolysis [105], and to attenuate the accumulation of ceramide
in muscles, associated with a high fat diet, resulting in
improved whole body glucose homeostasis [106] and amelio-
ration of prediabetic type 2 disposition. Previous reports also
provided promising results with complete reversal of diabetes
(6/11 mice) in obese mice with continuous administration
of FTY720 [107]. In addition, the recent study by Moon
and colleagues demonstrated that FTY720 increased 𝛽-cell
survival and restored 𝛽-cell function with improved glucose
tolerance in a diabetic (db/db) mouse model [108]. Not all
groups have found FTY720 beneficial in the prevention or
cure of diabetes [86, 109]. Fayyaz and colleagues demon-
strated FTY720 was unable to modulate S1Pmediated insulin
signalling in human and rat hepatocytes [86]. As mentioned,





receptor in insulin resistance was demonstrated
by blocking the receptor using a specific antagonist (JTE-
013), thereby increasing hepatic insulin signalling [86, 109].
Hence specific S1P
2
receptor antagonists such as JTE-013
have been suggested as targets for diabetes treatments
(Figure 2).
The controversial function of current S1P agonists and
functional antagonists has been associated with binding of
differing S1P receptor transmembrane expression, such as
demonstrated for FTY720. As discussed above, SphK1/S1P
inhibitors can have positive and negative impact for dia-
betic patients depending on the patient’s specific con-
dition. Current second generation S1P receptor agonists
hold much promise for comorbidity cancer/diabetes treat-
ments and are reviewed in [88, 89]. A comparison of
fingolimod (FTY720) and the most advanced next gen-
eration S1P modulators (siponimod, ponesimod, KRP-203,

























receptormodulates hepatic insulin signalling. FTY720 binds to S1P
1,3−5





has been associated with impaired insulin signalling [86, 109]. FTY720 is a S1P
1,3−5
agonist but also acts as a functional
antagonist of S1P
1
[109]. FTY720 does not bind to S1P
2
and therefore does not affect S1P
2





























Figure 3: Balancing the SphK1/S1P rheostat for diabetes and cancer comorbidity treatments. Second generation S1P receptor modulators are
currently being developed to target individual and multiple S1P receptors. Each of the receptor modulators binds to individual or multiple
receptors to block or activate the S1P receptor. Siponimod is a S1P
1,4,5
modulator; ponesimod is an agonist for S1P
1,3,4
; KRP-203 is an agonist
for S1P
1,4
; ONO-4641 is an agonist for S1P
1,4,5
; RPC1063 is an agonist for S1P
1,4,5
; Cs-0777 is an agonist for S1P
1,3,5
; GSK2018682 is an agonist
for S1P
1,5
. FTY720 and JTE-013 are described in Figure 2. These novel S1P receptors and downstream signalling pathways and functions are
reviewed in [88, 93]. Sipon: siponimod; pone: ponesimod; FTY: FTY720.
ONO-4641, RPC1063, CS-0777, and GSK2018682), each
modulator targeting common and different S1P receptors, are
illustrated in Figure 3 [88, 93]. Comparative selectivity of S1P
modulator activation of specific S1P receptors is shown in
Table 1. Knowledge of specific S1P receptor function provides
some insight into how S1P receptor modulators may be
targeted for comorbidity treatments.
7. The SphK1/S1P Rheostat
Therapeutic Challenge
Targeting the sphingolipid rheostat for diabetes and cancer
therapy holds great promise; however, the treatment for
comorbidity will be the greatest hurdle to overcome. As
portrayed in Figure 1, the challenge will be to balance cancer
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FTY720 ++++ − + ++ +++
CS-0777 +++ − + − ++
Ponesimod +++ − + − ++
RPC0163 ++++ +/− +/− +/− ++
ONO-4641 ++ − − + ++
Siponimod ++ − − + ++
GSK2018682 ++ − − − +
KRP-203 +++ − − ++ −
JTE-013 − +++ − − −
+ indicates comparative selectivity of S1P modulators binding to individual
receptors.
cell apoptosis on the one hand and promote 𝛽-cell survival
for insulin production on the other hand; it is a swinging
pendulum (Figure 1). A greater understanding of the actions
of SphK1/S1P in the context of diabetes, especially the onset of
type 2 diabetes and cancer, is required if we are to switch the
sphingolipid rheostat in the treatment of diabetes and cancer
comorbidity from a problem to an advantage.
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